FDA now concludes "t he totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i Further evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and published Real-world success and experiences from dermatologists and general practice veterinarians around the U.S. and the world furth...
Elanco Animal Health Incorporated (NYSE:ELAN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Hi. Good morning, everyone.
Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales milestone Zenrelia™ (ilunocitinib tablets) now in ...
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind. , Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners to sponsor Nutrition Secure Indianapolis, a fir...
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acq...
GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.
Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.
I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive ou...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.